Supplementary Figure 2: A. Representative gating strategy for quantification of PMN-MDSCs, M-MDSCs, Ly6C+Mo-MØs, Alveolar macrophages (AMs), Interstitial macrophages (IMs) and myeloid DCs in the lungs of tumor-bearing mice. B. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the lungs of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes and of naïve mice. C. Quantitation of CD4+ and CD8+ T cells in the lungs of MOC2 WT/KO-Gal1 tumor-bearing mice at matched tumor volumes. D. Quantitation of CD8+ T cells in the blood after treatment with either isotype control IgG or anti-mouse CD8a antibody (clone 2.43, BioXCell, 400 µg i.p. twice weekly) in mice bearing MOC2 WT- or KO-Gal1 tumors. E. Quantitation of PMN-MDSCs in the lungs after treatment with either isotype control IgG or anti-mouse CD8a antibody i.p. twice weekly in mice bearing MOC2 WT- or KO-Gal1 tumors. Each dot represents one mouse, and the bar denotes the mean. Student's t-test (two-tailed) was used to compare the two groups. One-way ANOVA with Tukey's adjustment was used to compare multiple treatments. Data are shown as mean+/-SD.

SUPPLEMENTARY FIGURE: 2